Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL - report from ASH 2025

from Medical Digest & Congress Report · host Medical Congress News

Anand A. Patel discusses the primary efficacy analysis of a Phase II study investigating tyrosine kinase inhibitor and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:primary-efficacy-analysis-tki-and-inotuzumab-ozogamicin-based-therapy-newly-diagnosed-ph-all

Episode metadata supplied by the publisher feed · Published Jan 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL - report from ASH 2025

0:00 4:38

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 4 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 7, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!